Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, And Blood, and Aging Diseases (R21)

The summary for the Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, And Blood, and Aging Diseases (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, And Blood, and Aging Diseases (R21): -This funding opportunity will define the factors and mechanisms controlling the differentiation of embryonic or adult stem or progenitor cells, either in vitro or in vivo. It is designed to stimulate new scientific advances in stem cell differentiation including technology research that may not be hypothesis driven. The long range goal of this program is the development of methods to direct the differentiation or development of stem cells along specific cell lineages to yield replacement cells for clinical use, whether the replacement cells are formed in vitro for delivery or formed in vivo in the tissue or organ environment. The total amount to be awarded and the anticipated number of awards. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -This PA will use the NIH R21 award mechanism. R21 applications should meet the requirements for this mechanism as recently redefined in PA-03-107, NIH Exploratory/Developmental Research Grant Award (R21); http://grants.nih.gov/grants/guide/pa-files/PA-03-107.html. -Eligible organizations include for-profit or non-profit organizations, public or private institutions, such as universities, colleges, hospitals, and laboratories, units of State and local governments, eligible agencies of the Federal government, domestic or foreign institutions/organizations, and faith-based or community-based organizations. -Eligible principal investigators are any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. -Each investigator may submit more than one application provided that the applications are substantively different from each other. -The application form is available at: http://grants1.nih.gov/grants/funding/phs398/phs398.html. -Telecommunications for the hearing impaired is available at: TTY 301-451-0088